Aaron Seth Kesselheim

Aaron Seth Kesselheim, MD, JD, MPH

Professor of Medicine
Member, HMS Center for Bioethics

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions-Reply.
Authors: Authors: Yeh JS, Franklin JM, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
Prescription Trends-Brand-Name Drugs vs Generic-Reply.
Authors: Authors: Kesselheim AS, Gagne JJ.
JAMA Intern Med
View full abstract on Pubmed
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015.
Authors: Authors: Deak D, Outterson K, Powers JH, Kesselheim AS.
Ann Intern Med
View full abstract on Pubmed
Generic Drug Approvals Since the 1984 Hatch-Waxman Act.
Authors: Authors: Gupta R, Kesselheim AS, Downing N, Greene J, Ross JS.
JAMA Intern Med
View full abstract on Pubmed
Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Authors: Authors: Luo J, Seeger JD, Donneyong M, Gagne JJ, Avorn J, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Authors: Authors: Kesselheim AS, Avorn J, Sarpatwari A.
JAMA
View full abstract on Pubmed
The FDA, Juno Therapeutics, and the ethical imperative of transparency.
Authors: Authors: Hey SP, Kesselheim AS.
BMJ
View full abstract on Pubmed
Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Authors: Authors: Yeh JS, Sarpatwari A, Kesselheim AS.
Drug Saf
View full abstract on Pubmed
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012.
Authors: Authors: Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS.
JACC Basic Transl Sci
View full abstract on Pubmed
Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
Authors: Authors: Gagne JJ, Polinski JM, Jiang W, Dutcher SK, Xie J, Lii J, Fulchino LA, Kesselheim AS.
Pharmacoepidemiol Drug Saf
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
Boston, MA 02120